Infliximab to treat severe ulcerative colitis

• Autor(a) principal: Cury, Didia Bisamra [UNIFESP]
• Data de Publicação: 2009
• Outros Autores: Cury, Marcelo de Souza [UNIFESP], Elias, Geraldo Vinicius Hemerly [UNIFESP], Mizsputen, Sender Lankiel [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• dARK ID: ark:/48912/0013000018mqz
• Texto Completo: http://dx.doi.org/10.3748/wjg.15.1771; http://repositorio.unifesp.br/handle/11600/31456
• topic: Cyclosporine; Infliximab; Treatment failure; Ulcerative colitis; Inflammatory bowel diseases

A 48-year-old female with severe ulcerative colitis refractory to conventional therapy was referred to our facility for management. the patient showed extensive ulcerative colitis since the age of 20 years and had failed therapy with 5-aminosalicylic acid agents and azathioprine. the disease remained active despite treatment with steroids and cyclosporine. the clinical and endoscopic parameters were consistent with severe disease. Infectious precipitants were ruled out. Given the severity of the disease and in order to avoid a colectomy, we started the patient on infliximab therapy. A dramatic clinical and endoscopic response was observed and she remained in remission at the end of a 1-year follow-up period. We discuss findings in the literature regarding the use of infliximab therapy in patients with ulcerative colitis who have failed steroids and cyclosporine. (C) 2009 the WJG Press and Baishideng. All rights reserved.